Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients

BMC Medical Genomics

Volumn 5, Issue , 2012, Pages

  Wang, Danxin ^a   Curtis, Amanda ^a   Papp, Audrey C ^a   Koletar, Susan L ^b   Para, Michael F ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Association; Glutamate cysteine ligase catalytic subunit (GCLC); HIV AIDS; Hypersensitivity; Idiosyncratic drug reaction; Sulfamethoxazole

Indexed keywords

COTRIMOXAZOLE; GLUTAMATE CYSTEINE LIGASE; GLUTAMATE CYSTEINE LIGASE CATALYTIC SUBUNIT; GLUTATHIONE; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; AIDS PATIENT; ARTICLE; B LYMPHOCYTE; CAT GENE; CAUCASIAN; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FMO1 GENE; FMO3 GENE; GCLC GENE; GCLM GENE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GSR GENE; GSRG6PD GENE; GSS GENE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MPO1 GENE; POPULATION RESEARCH; PRIORITY JOURNAL; PTGS1 GENE; PTGS2 GENE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SOD1 GENE; SOD2 GENE; SOD3 GENE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; CATALYTIC DOMAIN; FEMALE; GENOTYPING TECHNIQUES; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE; HIV INFECTIONS; HUMANS; HYPERSENSITIVITY; MALE; METABOLIC DETOXICATION, DRUG; POLYMORPHISM, SINGLE NUCLEOTIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84865226135     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-5-32     Document Type: Article

References (52)

1. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Cote d'Ivoire: a trial-based analysis. Yazdanpanah Y, Losina E, Anglaret X, Goldie SJ, Walensky RP, Weinstein MC, Toure S, Smith HE, Kaplan JE, Freedberg KA, Aids 2005 19 1299 1308 10.1097/01.aids.0000180101. 80888.c6 16052085 (Pubitemid 41224899)
2. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Rodriguez M, Fishman JA, Clin Microbiol Rev 2004 17 770 782 table of contents 10.1128/CMR.17.4.770- 782.2004 15489347 (Pubitemid 39372516)
3. Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. Ju C, Uetrecht JP, Curr Drug Metab 2002 3 367 377 10.2174/1389200023337333 12093356 (Pubitemid 34778003)
4. Role of bioactivation in drug-induced hypersensitivity reactions. Sanderson JP, Naisbitt DJ, Park BK, Aaps J 2006 8 55 E64 10.1208/aapsj080107 16584134 (Pubitemid 44603864)
5. Genetic factors in the predisposition to drug-induced hypersensitivity reactions. Pirmohamed M, Aaps J 2006 8 20 E26 10.1208/aapsj080103 16584129 (Pubitemid 44603868)
6. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Cribb AE, Spielberg SP, Griffin GP, Drug Metab Dispos 1995 23 406 414 7628308
7. Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Winter HR, Unadkat JD, Drug Metab Dispos 2005 33 969 976 10.1124/dmd.104.002998 15843491 (Pubitemid 41002779)
8. Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs. Cribb AE, Miller M, Tesoro A, Spielberg SP, Mol Pharmacol 1990 38 744 751 2172779
9. Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: II. Expression and role of flavin-containing monooxygenases and peroxidases. Vyas PM, Roychowdhury S, Koukouritaki SB, Hines RN, Krueger SK, Williams DE, Nauseef WM, Svensson CK, J Pharmacol Exp Ther 2006 319 497 505 10.1124/jpet.106.105874 16857727 (Pubitemid 44455157)
10. synthases and their importance in chemical toxicity. Vogel C, Prostaglandin H, Curr Drug Metab 2000 1 391 404 10.2174/1389200003338884 11465045
11. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity. Cribb AE, Miller M, Leeder JS, Hill J, Spielberg SP, Drug Metab Dispos 1991 19 900 906 1686233
12. In vitro formation, disposition and toxicity of N-acetoxy- sulfamethoxazole, a potential mediator of sulfamethoxazole toxicity. Nakamura H, Uetrecht J, Cribb AE, Miller MA, Zahid N, Hill J, Josephy PD, Grant DM, Spielberg SP, J Pharmacol Exp Ther 1995 274 1099 1104 7562475
13. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Naisbitt DJ, Farrell J, Gordon SF, Maggs JL, Burkhart C, Pichler WJ, Pirmohamed M, Park BK, Mol Pharmacol 2002 62 628 637 10.1124/mol.62.3.628 12181439 (Pubitemid 36329381)
14. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT, Lancet 2002 359 727 732 10.1016/S0140-6736(02)07873-X 11888582 (Pubitemid 34215071)
15. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. Littera R, Carcassi C, Masala A, Piano P, Serra P, Ortu F, Corso N, Casula B, La Nasa G, Contu L, Manconi PE, Aids 2006 20 1621 1626 10.1097/01.aids.0000238408. 82947.09 16868443 (Pubitemid 44162404)
16. Medical genetics: a marker for Stevens-Johnson syndrome. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT, Nature 2004 428 486 10.1038/428486a 15057820 (Pubitemid 38480527)
17. The role of dose distribution gradient in the observed ferric ion diffusion time scale in MRI-Fricke-infused gel dosimetry. Tseng YJ, Chu WC, Chung WY, Guo WY, Kao YH, Wang J, Huang SC, Magn Reson Imaging 2002 20 495 502 10.1016/S0730-725X(02)00522-2 12361797 (Pubitemid 35176144)
18. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, Wright TM, Meyer J, Paulding CA, Nat Genet 2010 42 711 714 10.1038/ng.632 20639878
19. HLA-B 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, Goldstein DB, John S, Nelson MR, Graham J, Park BK, Dillon JF, Bernal W, Cordell HJ, Pirmohamed M, Aithal GP, Day CP, Nat Genet 2009 41 816 819 10.1038/ng.379 19483685
20. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, Carlsson S, Cederbrant KE, Gibson NJ, Armstrong M, Lagerstrom-Fermer ME, Dellsen A, Brown EM, Thornton M, Dukes C, Jenkins SC, Firth MA, Harrod GO, Pinel TH, Billing-Clason SM, Cardon LR, March RE, Pharmacogenomics J 2008 8 186 195 10.1038/sj.tpj.6500458 17505501 (Pubitemid 351712643)
21. Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype. Ozkaya-Bayazit E, Akar U, J Am Acad Dermatol 2001 45 712 717 10.1067/mjd.2001.117854 11606921 (Pubitemid 33032568)
22. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, Schumacher M, Roujeau JC, Hovnanian A, Mockenhaupt M, Pharmacogenet Genomics 2008 18 99 107 10.1097/FPC.0b013e3282f3ef9c 18192896
23. TNF, LTA, HSPA1L and HLA-DR gene polymorphisms in HIV-positive patients with hypersensitivity to cotrimoxazole. Alfirevic A, Vilar FJ, Alsbou M, Jawaid A, Thomson W, Ollier WE, Bowman CE, Delrieu O, Park BK, Pirmohamed M, Pharmacogenomics 2009 10 531 540 10.2217/pgs.09.6 19374512
24. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT, Proc Natl Acad Sci U S A 2005 102 4134 4139 10.1073/pnas.0409500102 15743917 (Pubitemid 40388568)
25. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W, Ann Intern Med 1986 105 179 184 3729200 (Pubitemid 16039289)
26. Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants. Zielinska E, Niewiarowski W, Bodalski J, Rebowski G, Skretkowicz J, Mianowska K, Sekulska M, Pharm World Sci 1998 20 123 130 10.1023/A:1008664707825 9618736 (Pubitemid 28204307)
27. N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Kaufmann GR, Wenk M, Taeschner W, Peterli B, Gyr K, Meyer UA, Haefeli WE, Clin Pharmacol Ther 1996 60 62 67 10.1016/S0009-9236(96) 90168-X 8689813 (Pubitemid 26279222)
28. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pirmohamed M, Alfirevic A, Vilar J, Stalford A, Wilkins EG, Sim E, Park BK, Pharmacogenetics 2000 10 705 713 10.1097/00008571-200011000-00005 11186133
29. Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. O'Neil WM, Drobitch RK, MacArthur RD, Farrough MJ, Doll MA, Fretland AJ, Hein DW, Crane LR, Svensson CK, Pharmacogenetics 2000 10 171 182 10.1097/00008571-200003000- 00009 10762005 (Pubitemid 30193079)
30. The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation. Gill HJ, Tjia JF, Kitteringham NR, Pirmohamed M, Back DJ, Park BK, Pharmacogenetics 1999 9 43 53 10.1097/00008571-199902000-00007 10208642 (Pubitemid 29176723)
31. Human N-acetyltransferase 1 10 and 11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity. Wang D, Para MF, Koletar SL, Sadee W, Pharmacogenet Genomics 2011 21 652 664 10.1097/FPC.0b013e3283498ee9 21878835
32. Genetic variation and antioxidant response gene expression in the bronchial airway epithelium of smokers at risk for lung cancer. Wang X, Chorley BN, Pittman GS, Kleeberger SR, Brothers J, Liu G, Spira A, Bell DA, PLoS One 2010 5 11934 10.1371/journal.pone.0011934 20689807
33. Association of polymorphism in glutamate-cysteine ligase catalytic subunit gene with coronary vasomotor dysfunction and myocardial infarction. Koide S, Kugiyama K, Sugiyama S, Nakamura S, Fukushima H, Honda O, Yoshimura M, Ogawa H, J Am Coll Cardiol 2003 41 539 545 12598062 (Pubitemid 36223316)
34. Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease. Oliveira CP, Stefano JT, Cavaleiro AM, Zanella Fortes MA, Vieira SM, Rodrigues Lima VM, Santos TE, Santos VN, de Azevedo Salgado AL, Parise ER, Ferreira Alves VA, Carrilho FJ, Correa-Giannella ML, J Gastroenterol Hepatol 2010 25 357 361 10.1111/j.1440-1746.2009.06001.x 19817962
35. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, Deppen P, Preisig M, Ruiz V, Steullet P, Tosic M, Werge T, Cuenod M, Do KQ, Proc Natl Acad Sci U S A 2007 104 16621 16626 10.1073/pnas.0706778104 17921251 (Pubitemid 350211066)
36. Oxidative stress mediated idiosyncratic drug toxicity. Tafazoli S, Spehar DD, O'Brien PJ, Drug Metab Rev 2005 37 311 325 15931767 (Pubitemid 40677507)
37. Roles of endogenous ascorbate and glutathione in the cellular reduction and cytotoxicity of sulfamethoxazole-nitroso. Lavergne SN, Kurian JR, Bajad SU, Maki JE, Yoder AR, Guzinski MV, Graziano FM, Trepanier LA, Toxicology 2006 222 25 36 10.1016/j.tox.2006.01.018 16473451
38. Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice. Choi J, Liu RM, Kundu RK, Sangiorgi F, Wu W, Maxson R, Forman HJ, J Biol Chem 2000 275 3693 3698 10.1074/jbc.275.5.3693 10652368 (Pubitemid 30083082)
39. Trimethoprim-sulfamethoxazole: an assessment of more than 12 years of use. Salter AJ, Rev Infect Dis 1982 4 196 236 10.1093/clinids/4.2.196 7051224
40. An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and gamma-glutamylcysteine synthetase knockdown cells. Hosomi H, Akai S, Minami K, Yoshikawa Y, Fukami T, Nakajima M, Yokoi T, Toxicol In Vitro 2010 24 1032 1038 10.1016/j.tiv.2009.11.020 19958826
41. A GAG trinucleotide-repeat polymorphism in the gene for glutathione biosynthetic enzyme, GCLC, affects gene expression through translation. Nichenametla SN, Lazarus P, Richie JP, FASEB J 2011 25 2180 2187 10.1096/fj.10-174011 21444626
42. Functional significance of the GAG trinucleotide-repeat polymorphism in the gene for the catalytic subunit of gamma-glutamylcysteine ligase. Nichenametla SN, Ellison I, Calcagnotto A, Lazarus P, Muscat JE, Richie JP, Free Radic Biol Med 2008 45 645 650 10.1016/j.freeradbiomed.2008.05.012 18549827
43. Skin fibroblast model to study an impaired glutathione synthesis: consequences of a genetic polymorphism on the proteome. Gysin R, Riederer IM, Cuenod M, Do KQ, Riederer BM, Brain Res Bull 2009 79 46 52 10.1016/j. brainresbull.2008.10.015 19041695
44. No association between glutathione-synthesis-related genes and Japanese schizophrenia. Hanzawa R, Ohnuma T, Nagai Y, Shibata N, Maeshima H, Baba H, Hatano T, Takebayashi Y, Hotta Y, Kitazawa M, Arai H, Psychiatry Clin Neurosci 2011 65 39 46 10.1111/j.1440-1819.2010.02157.x 21105962
45. Evaluation of the impact of genetic polymorphisms in glutathione-related genes on the association between methylmercury or n-3 polyunsaturated long chain fatty acids and risk of myocardial infarction: a case-control study. Engstrom KS, Wennberg M, Stromberg U, Bergdahl IA, Hallmans G, Jansson JH, Lundh T, Norberg M, Rentschler G, Vessby B, Skerfving S, Broberg K, Environ Health 2011 10 33 10.1186/1476-069X-10-33 21504558
46. Association of polymorphisms in glutamate-cysteine ligase catalytic subunit and microsomal triglyceride transfer protein genes with nonalcoholic fatty liver disease. Hashemi M, Hoseini H, Yaghmaei P, Moazeni-Roodi A, Bahari A, Hashemzehi N, Shafieipour S, DNA Cell Biol 2011 30 569 575 10.1089/dna.2010.1162 21438662
47. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W, Pharmacogenomics J 2011 11 274 286 10.1038/tpj.2010.28 20386561
48. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Lucena MI, Garcia-Martin E, Andrade RJ, Martinez C, Stephens C, Ruiz JD, Ulzurrun E, Fernandez MC, Romero-Gomez M, Castiella A, Planas R, Duran JA, De Dios AM, Guarner C, Soriano G, Borraz Y, Agundez JA, Hepatology 2010 52 303 312 10.1002/hep.23668 20578157
49. Sensitivity of liver injury in heterozygous Sod2 knockout mice treated with troglitazone or acetaminophen. Fujimoto K, Kumagai K, Ito K, Arakawa S, Ando Y, Oda S, Yamoto T, Manabe S, Toxicol Pathol 2009 37 193 200 10.1177/0192623308329282 19332662
50. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Enomoto A, Itoh K, Nagayoshi E, Haruta J, Kimura T, O'Connor T, Harada T, Yamamoto M, Toxicol Sci 2001 59 169 177 10.1093/toxsci/59.1.169 11134556 (Pubitemid 32117993)
51. Genotyping panel for assessing response to cancer chemotherapy. Dai Z, Papp AC, Wang D, Hampel H, Wolfgang S, BMC Med Genomics 2008 1 24 10.1186/1755-8794-1-24 18547414
52. Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues. Wang D, Papp AC, Binkley PF, Johnson JA, Sadee W, Pharmacogenet Genomics 2006 16 735 745 10.1097/01.fpc.0000230119.34205.8a 17001293 (Pubitemid 44454868)